ConferenceSeries

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

 

Biography

Sabah Akrawi, Ph.D., graduated from the College of Pharmacy/University of Kentucky/USA. He is an assoc. Prof. of Clinical Pharmacokinetic and Biopharmaceutic and a faculty member at the College of Clinical Pharmacy/King Faisal University/KSA. He supervised 17 post graduate pharmacy students, and he has published more than 24 articles. He is a member of the scientific council of the KFU and chaired many defense committees for graduation of graduate students.

Abstract

Black tea extract (leaves and leaf buds of the plant Camella sinensis) consumption is generally thought to be safe and does not cause medical problem. Carbamazepine (CBZ) is used for the treatment of epileptic patients and it is extensively metabolized by liver enzymes. However, tea components (Caff eine, Th eophylline, and Th eobromine) induce liver enzymes; it may induce the metabolism of CBZ. Furthermore, physician should be aware regarding this interaction. The aim of this study is to predict the possibility of interactions of tea components with the disposition of Carbamazepine (CBZ) in epileptic patients. Th e pharmacokinetic parameters CBZ steady state serum concentrations (CSS) and total CBZ clearances (ClT) were estimated. This study was conducted on thirty six epileptic patients, they were allocated into four groups, patients in group (I) and (II) were already on chronic CBZ treatment, while patients in group (III) and (IV) initiate CBZ therapy during the study. Th e (CSS) for patients in group (I & III), who were tea drinker, are signifi cantly increased aft er (7) days of stopping tea consumption, and (ClT) are significantly decreased. Th e (CSS) for patients of groups (II & IV), who drunk no tea for 7 days before sampling, are signifi cantly decreased after (7) days of drinking tea and the (ClT) are significantly increased. Th e total volume of tea given to the patients in each group is about (400 ml/day). According to these results epileptic patients, who are tea drinker, treated with CBZ required therapeutic drug monitoring.

Speaker Presentations

Speaker PDFs

Conference Series Destinations

Contact Us

Medical Conferences
Jessie Grace
jessie.grace@conferenceseries.com
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
badoni.victor@conferenceseries.com
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
walker.smith@conferenceseries.com
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
jennifer.leny@conferenceseries.com
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
stanley.knight@conferenceseries.com
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
sandeep@conferenceseries.com
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
rohit.casper@conferenceseries.com
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
ravi.vittal@conferenceseries.com
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
lucygrey@conferenceseries.com
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
stephen.bruce@conferenceseries.com
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
dolly@conferenceseries.com
+1-702-508-5200 Ext:8051

Program Enquiries
Symposia/Workshops
Sponsorships
Media Partners | Advertising